Results 151 to 160 of about 12,153 (191)
A PRISMA-guided systematic review of pharmacogenetic anticancer clinical trials registered on clinicaltrials.gov. [PDF]
Medicine (Baltimore)Ashour AM, Alhayyan A, Alhayyan R.
europepmc +1 more source
Inhibition of UGT1A1 by natural and synthetic flavonoids [PDF]
International Journal of Biological Macromolecules, 2019 Flavonoids are widely distributed phytochemicals in vegetables, fruits and medicinal plants. Recent studies demonstrate that some natural flavonoids are potent inhibitors of the human UDP-glucuronosyltransferase 1A1 (UGT1A1), a key enzyme in ...
Hui Tang, Chun-Zhi Ai, Guangbo Ge
exaly +6 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Molecular Biology Reports, 2021
Gilbert's syndrome is characterized by mild unconjugated hyperbilirubinemia. The key of this disease is a diminished activity of UDP-glucuronosyltransferase 1A1 (UGT1A1). TA insertion into the TATA box promoter region of the UGT1A1 gene on chromosome 2 is the genetic basis of Gilbert's syndrome (UGT1A1*28).
Ilaria GALLIANO +2 more
exaly +4 more sources
Gilbert's syndrome is characterized by mild unconjugated hyperbilirubinemia. The key of this disease is a diminished activity of UDP-glucuronosyltransferase 1A1 (UGT1A1). TA insertion into the TATA box promoter region of the UGT1A1 gene on chromosome 2 is the genetic basis of Gilbert's syndrome (UGT1A1*28).
Ilaria GALLIANO +2 more
exaly +4 more sources
The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan
ESMO Open, 2023 [[abstract]]Background: Initial dose adjustment is recommended for patients with known UGT1A1∗28 homozygosity for both conventional irinotecan and liposomal irinotecan (nal-IRI).
Yan-Shen Shan, Li-Tzong Chen, Y-S Shan
exaly +2 more sources
Inhibition of UGT1A1*1 and UGT1A1*6 catalyzed glucuronidation of SN-38 by silybins
Chemico-Biological Interactions, 2022UGT1A1 is the main enzyme that catalyzes the metabolic elimination and detoxification of SN-38, the active form of the drug irinotecan. Milk thistle products have been used widely to protect the liver from injury associated with the use of chemotherapeutic agents.
Yong Liu
exaly +3 more sources
UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation
Cancers, 2021 Multi-gene assays often include UGT1A1 and, in certain instances, may report associated toxicity risks for irinotecan, belinostat, pazopanib, and nilotinib.
Sandra M. Swain, Nathan D Seligson
exaly +2 more sources
Variation in UGT1A1 activity in Gilbert's syndrome
Journal of Hepatology, 2001.
Ostrow, Jd, TIRIBELLI, CLAUDIO
openaire +4 more sources
Medical Oncology, 2013 The aim of this study was to investigate the associations between UDP-glucuronosyltransferase (UGT) 1A1 polymorphisms and irinotecan-induced toxicities in Chinese advanced colorectal cancer patients.
Lin Shen, Jing Gao, Ru Jia
exaly +2 more sources
Asia-Pacific Journal of Clinical Oncology, 2018
AbstractBackgroundPrevious articles explored the role of UGT1A1 polymorphism on predicting irinotecan‐induced toxicity, but the conclusions were still inconsistent and not comprehensive. We performed this meta‐analysis to investigate the association between UGT1A1 polymorphism and irinotecan‐induced toxicity.MethodsPubMed and Web of Science were ...
Fen Huang
exaly +3 more sources
AbstractBackgroundPrevious articles explored the role of UGT1A1 polymorphism on predicting irinotecan‐induced toxicity, but the conclusions were still inconsistent and not comprehensive. We performed this meta‐analysis to investigate the association between UGT1A1 polymorphism and irinotecan‐induced toxicity.MethodsPubMed and Web of Science were ...
Fen Huang
exaly +3 more sources
European Journal of Drug Metabolism and Pharmacokinetics, 2021
Irinotecan (CPT-11) is metabolized to an active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) by carboxylesterase (CES). SN-38 is then converted to the inactive metabolite SN-38 glucuronide (SN-38G) by glucuronosyltransferase 1A1 (UGT1A1). Genetic polymorphisms in UGT1A1 have been associated with altered SN-38 pharmacokinetics, which increase the ...
Akitomo Yokokawa +13 more
openaire +2 more sources
Irinotecan (CPT-11) is metabolized to an active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) by carboxylesterase (CES). SN-38 is then converted to the inactive metabolite SN-38 glucuronide (SN-38G) by glucuronosyltransferase 1A1 (UGT1A1). Genetic polymorphisms in UGT1A1 have been associated with altered SN-38 pharmacokinetics, which increase the ...
Akitomo Yokokawa +13 more
openaire +2 more sources